SKU: n/a.
Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analogue that stimulates pulsatile endogenous growth hormone (GH) secretion, leading to significant reductions in visceral adipose tissue (VAT) and improvements in metabolic markers, without clinically relevant liver toxicity. Supplied as a high‐purity, lyophilized powder, it’s ideal for precise research applications in metabolism, adipose biology, and endocrine regulation.
**Disclaimer:** This product is sold for research and development purposes only. It is not intended for human consumption or therapeutic use. Not evaluated by the FDA.
This product is currently out of stock and unavailable.
Description Additional information Reviews (0)
Overview
Tesamorelin is a synthetic GHRH analogue developed to treat visceral adiposity by mimicking endogenous GHRH signaling and promoting pulsatile GH release NCBIDrugBank. It is administered via subcutaneous injection, undergoing proteolytic metabolism and renal excretion, with bioavailability ≤ 4 % when delivered by this route WikipediaMayo Clinic. Tesamorelin’s elimination half‐life ranges from 26 to 38 minutes, allowing naturalistic GH pulse patterns without receptor desensitization WikipediaPubChem.
Key Features
Pulsatile GH Stimulation: Binds GHRH receptors on anterior pituitary somatotrophs, eliciting dose‐dependent, pulsatile GH release that enhances IGF‐1 production PubMed.
Visceral Fat Reduction: Phase 3 trials in HIV‐associated lipodystrophy showed VAT reductions of 15–18 % maintained through 52 weeks, with preservation of subcutaneous adipose tissue and favorable lipid profile changes PubMedNCBI.
Metabolic Benefits: Improves glucose homeostasis and lipid metabolism, reducing triglycerides and improving HDL levels without clinically meaningful alterations in fasting glucose or insulin PubMedNCBI.
High Purity & Stability: Lyophilized powder verified at ≥ 99 % purity by reverse‐phase HPLC; freeze‐drying ensures long shelf life and rapid reconstitution in aqueous buffer Analytical Science Journals.
Clean Safety Profile: Not linked to clinically apparent liver injury; adverse events are primarily mild (erythema at injection site, arthralgia) with no significant impact on liver enzymes or cortisol levels NCBINCBI.
Applications
Adipose Biology Research: Model VAT dynamics, lipolysis, and adipocyte differentiation in human and animal studies PubMed CentralScienceDirect.
Endocrine & Metabolic Studies: Investigate GH/IGF‐1 axis feedback, insulin sensitivity, and lipid handling in vitro and in vivo Synapse.
Drug Interaction & Safety Assays: Evaluate off‐target effects, hepatic safety, and peptide stability under varied physiological conditions NCBIMayo Clinic.
Formulation & Delivery Research: Assess subcutaneous injection parameters, peptide solubility, and pharmacokinetic modeling for extended‐release designs FDA Access DataMayo Clinic.
Biomarker Development: Use IGF‐1 and VAT measurements as biomarkers for peptide efficacy and metabolic health endpoints NCBIPubMed Central.
Specifications
Attribute Specification Form White to off‐white lyophilized powder Purity ≥ 99 % by reverse‐phase HPLC Molecular Weight 4887.1 Da (as acetate salt) Sequence Tyr1‐dTrp2(Glu3‐Gln4) ... total 44 amino acids † Bioavailability ≤ 4 % (subcutaneous) Elimination T1⁄2 26–38 minutes in healthy and HIV‐infected subjects CAS Number 218949‐48‐5 Storage −20 °C, dry, protected from light (stable ≥ 2 years)
Weight 0.1 oz Size
10mg
© 2025 — Advanced Research — 1650 W. Targee St. Unit 5952. Boise, ID. 83705